Company intelligence / Profile preview

KGK Science

Ownership: Private
Employees: ~135
Development stage: Commercial

Overview

KGK Science has conducted over 400 clinical trials across more than 40 indications since its founding in 1997. The company specializes in claim substantiation and regulatory support for natural health products including nutraceuticals, cannabis/hemp-derived products, and psychedelics. It was the first Canadian CRO to obtain a Cannabis Research License and has produced over 150 publications. Recent projects include running psilocybin clinical trials for Fragile X syndrome.

Therapeutic areas: OtherPsychiatryNeurology
Modalities: Small moleculePsychedelic therapyBiologicDevice
Industry: Contract Research Organization

Partnerships

Nova Mentis Life Science Corp.

Beyond the preview

Go deeper on KGK Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KGK Science.

Explore the full profile